financetom
Business
financetom
/
Business
/
AptarGroup Q4 Non-GAAP Earnings Fall, Revenue Rises; Shares Advance After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AptarGroup Q4 Non-GAAP Earnings Fall, Revenue Rises; Shares Advance After Hours
Mar 11, 2026 3:12 AM

05:33 PM EST, 02/05/2026 (MT Newswires) -- AptarGroup ( ATR ) reported Q4 non-GAAP net income late Thursday of $1.25 per diluted share, down from $1.62 a year earlier.

Analysts polled by FactSet expected $1.23.

Net sales in the three months ended Dec. 31 rose to $962.7 million, up from $848.1 million a year earlier.

Analysts surveyed by FactSet expected $878.6 million.

The company expects Q1 adjusted EPS of $1.13 to $1.21. Analysts polled by FactSet project $1.15.

AptarGroup ( ATR ) shares rose 4.9% in after-hours trading.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bayer settles Sky Valley cases over chemical PCB
Bayer settles Sky Valley cases over chemical PCB
Aug 18, 2025
Aug 18 (Reuters) - Bayer said on Monday its Monsanto unit reached agreements in principle with more than 200 plaintiffs to resolve the so-called Sky Valley Education Center product liability cases related to the chemical PCB. Bayer said in its statement that the terms of the agreements over environmental pollution with PCB, short for polychlorinated biphenyls, were confidential and subject...
Enlivex Therapeutics Says Allocetra Showed Improvements in Phase IIa Trial for Osteoarthritis
Enlivex Therapeutics Says Allocetra Showed Improvements in Phase IIa Trial for Osteoarthritis
Aug 18, 2025
08:25 AM EDT, 08/18/2025 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) shares were up over 11% premarket Monday after the company said its Allocetra cell therapy demonstrated improvements in a phase IIa trial in patients with moderate-to-severe knee osteoarthritis. The Allocetra treatment arm showed a 24% reduction in knee pain and a 26% improvement in knee function compared with...
Catheter Precision Receives UK Approval for Suture Retention Device
Catheter Precision Receives UK Approval for Suture Retention Device
Aug 18, 2025
08:24 AM EDT, 08/18/2025 (MT Newswires) -- Catheter Precision ( VTAK ) said Monday that it has received registration and approval in the UK for its LockeT suture retention device, allowing it to launch sales in the nation. Catheter Precision ( VTAK ) said it has entered into an agreement with UK-based HC21 to distribute LockeT. LockeT received a CE...
Ultragenyx Pharmaceutical Begins Biologics License Application for Glycogen Storage Disease Gene Therapy
Ultragenyx Pharmaceutical Begins Biologics License Application for Glycogen Storage Disease Gene Therapy
Aug 18, 2025
08:23 AM EDT, 08/18/2025 (MT Newswires) -- Ultragenyx Pharmaceutical ( RARE ) said Monday it initiated a rolling submission of a biologics license application for its DTX401 AAV gene therapy as treatment for glycogen storage disease Type Ia with the US Food and Drug Administration. The company said it aims to complete the full application, including submission of the chemistry,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved